DeepMind
AI
Isomorphic Labs Enters Human Trials With AI-Designed Drugs, Testing Industry’s $3 Billion Bet
DeepMind spinoff's 2026 clinical trials mark first major test of whether machine learning can genuinely reduce drug failure rates beyond early-stage screening.
AI
Bridgewater’s Chief Scientist Joins DeepMind as Wall Street AI Talent Flows to Tech Giants
Jasjeet Sekhon's move from systematic investing to Google's AI research arm reveals how foundational machine learning capabilities are migrating from finance to tech—and what it means for both industries.